NASDAQ · Biotechnology · USD

Addex Therapeutics Ltd (ADXN) Stock Analysis

Addex Therapeutics Ltd (ADXN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

ADXN

$3.65

−$0.06 (−1.62%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ADXN with… →

ADXN Key Statistics

As of Sep 4, 2026

Trading

Open: $3.69
Previous Close: $3.71
Day's Range: 3.62–3.91
52-Week Range: 3.40–12.05
Volume: 134.00K
Beta: 1.96

Valuation

Market Cap: $4.62M
P/E Ratio: unprofitable
P/S ratio: 42.20
EPS (ttm): −8.59

Financials (FY)

Revenue (FY): $29.97K−92.58%
Net Income (FY): −$6.73M−195.36%
Profit margin: 0.00%
Shares Outstanding: 1.27M
1-Year Return: −54.88%

Dividend and dates

Avg Volume: 134.22K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ADXN Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

+18.58%−53.06%−89.98%−51.98%+15.70%+10.29%−52.72%

2020*202120222023202420252026*

Year	Return
2026 (partial year)	−52.72%
2025	+10.29%
2024	+15.70%
2023	−51.98%
2022	−89.98%
2021	−53.06%
2020 (partial year)	+18.58%

As of September 4, 2026.

ADXN Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$29.97K	−$6.73M	−22448.4%
2024	$404.10K	$7.06M	1746.0%
2023	$1.61M	−$10.56M	−654.5%
2022	$1.42M	−$20.80M	−1462.6%

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$29.97K	—	−$2.81M	−$6.73M	−22448.4%
2024	$404.10K	—	−$2.76M	$7.06M	1746.0%
2023	$1.61M	—	−$2.24M	−$10.56M	−654.5%
2022	$1.42M	—	−$10.54M	−$20.80M	−1462.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ADXN Valuation vs Biotechnology Median

Median of 656 stocks

Metric	ADXN	Biotechnology median	vs median
P/S ratio	42.20	15.26	176% above
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Addex Therapeutics Ltd (ADXN) is capitalised at $4.62M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 3 employees.

The 52-week range on file runs from $3.40 to $12.05. ADXN last closed at $3.65 on September 4, 2026. That is −$0.06 (−1.62%) against the previous close. The latest close sits 7.35% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $29.97K. That is −92.58% against the prior fiscal year, when revenue was $404.10K. The same year closed with a net loss of $6.73M. Profit margin runs at 0%. Trailing earnings per share are −8.59.

Across the 4 fiscal years on file, revenue moves from $1.42M in 2022 to $29.97K in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 42.2. On price-to-sales that is 176.45% above the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 1.96. Daily returns over the trailing 6 years annualize to a volatility of 114.19%. Over the trailing twelve months the price has returned −54.88%. Across 5 years the annualized return works out at −54.63%.

Growth & Income

The record shows no dividend for ADXN.

The strongest complete calendar year on file is 2024 at +15.70%; the weakest is 2022 at −89.98%. Of the 5 complete calendar years on file, 2 finished higher. So far in 2026 the price is −52.72%.

Peer Comparison

Addex Therapeutics Ltd (ADXN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Addex Therapeutics Ltd	ADXN	$4.62M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Addex Therapeutics Ltd has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Addex Therapeutics Ltd

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-induced dyskinesia. The company also develops ADX71149, which is in phase 1 for undisclosed indication; and GABAB PAM for the treatment pain, anxiety, addiction, chronic cough, and overactive bladder. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the develop mGlu2 PAM compounds for the treatment of human health; and license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.

Visit website →